A Single-blind, Randomized, Parallel group study to evaluate antipyretic effect of Unani Medicine formulation– Cap Mubarak compared to controlled drug Tab Paracetamol in patients with Humma (fever) - Not applicable

Central Council for Research in Unani Medicine CCRUM New Delhi0 个研究点目标入组 0 人开始时间: 待定最近更新: 2024年3月4日

试验速览

暂无简介。

•1. Participants of either sex in the age group 18 to 65 years.
•2. History of onset of fever within 24 hr.
•3. Participants with oral temperature 100 F- 102 F presenting with any of the following symptoms:
•Joints pain
•Palpitation
•Skin Flushing

•1. Intake of any antipyretic drugs in the previous 8 hrs.
•2. Participant having oral temperature of greater than 102 F.
•3. Known high risk clinical conditions such as pneumonia, sepsis, dengue haemorrhagic fever,meningitis, hepatitis B, etc.
•4. Known cases of Immuno-compromised clinical conditions such as HIV, cancer etc.
•5. Known cases of other clinically significant co-morbid conditions (severe hepatic, renal, cardiovascular disorders, etc.) that in the opinion of the investigator could affect the efficacy and safety outcome of the study.
•6. Thrombocytopenia i.e. absolute platelet count below 1,00,000.
•7. Known hypersensitivity to study drug or any of its ingredients.
•8. Pregnant and Lactating females.
•9. Diabetes Mellitus or any systemic disorder requiring prolonged treatment.

发起方

Central Council for Research in Unani Medicine CCRUM New Delhi